Logotype for Qiagen N.V.

Qiagen (QGEN) Q4 2023 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Qiagen N.V.

Q4 2023 earnings summary

16 Oct, 2026

Executive summary

  • Q4 net sales were $509M (+2% reported, +1% CER); adjusted diluted EPS was $0.55 CER, above the $0.53 CER outlook, with 8% CER growth in non-COVID products.

  • FY 2023 sales were $1.97B, meeting CER outlook; non-COVID products grew 8% CER and adjusted diluted EPS of $2.09 CER exceeded the $2.07 CER outlook.

  • Q4 adjusted operating margin improved to 28.0% from 27.1% YoY; FY adjusted operating margin was 26.9% versus 30.6% in 2022.

Financial highlights

  • Q4 reported operating income was $110.6M, net income $97.7M and diluted EPS $0.42; adjusted net income was $127.2M and adjusted diluted EPS $0.55.

  • FY reported operating income was $409.9M, net income $341.3M and diluted EPS $1.48; adjusted operating income was $528.6M, adjusted net income $476.9M and adjusted diluted EPS $2.07.

  • Q4 adjusted gross margin was 65.7%, down from 67.0% YoY; lower capacity utilization and adverse product mix weighed on margin.

  • Operating cash flow was $459M and free cash flow $310M in FY 2023, versus $715M and $586M, respectively, in 2022.

Outlook and guidance

  • FY 2024 net sales expected at least $2.0B CER, representing at least 2% CER growth; non-COVID sales growth is expected to reach a solid mid-single-digit rate in H2.

  • Adjusted diluted EPS expected at least $2.10 CER; adjusted operating margin projected above 28%, improving at least 1 percentage point YoY while supporting portfolio investment.

  • Guidance includes ~1 percentage point of COVID-19 sales headwinds from 2023; consumables and related revenues are expected to drive growth, while larger-scale instrument sales remain challenging.

  • FY 2024 non-operating income faces significant pressure from lower interest income and a higher tax rate; currency is expected neutral for sales and to reduce adjusted EPS by ~$0.01 per share.

  • Q1 2024 net sales expected at least $455M CER and adjusted diluted EPS at least $0.44 CER; currency impact expected neutral on sales and negative ~$0.01 per share on adjusted EPS.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Qiagen